1. Home
  2. INBS vs BIAF Comparison

INBS vs BIAF Comparison

Compare INBS & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Intelligent Bio Solutions Inc.

INBS

Intelligent Bio Solutions Inc.

HOLD

Current Price

$2.51

Market Cap

4.4M

Sector

Health Care

ML Signal

HOLD

Logo bioAffinity Technologies Inc.

BIAF

bioAffinity Technologies Inc.

HOLD

Current Price

$0.40

Market Cap

4.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INBS
BIAF
Founded
2016
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.4M
4.5M
IPO Year
2019
2022

Fundamental Metrics

Financial Performance
Metric
INBS
BIAF
Price
$2.51
$0.40
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
91.2K
1.8M
Earning Date
05-08-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,980,484.00
$7,900,000.00
Revenue This Year
$778.48
$20.95
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
14.49
52 Week Low
$0.54
$0.23
52 Week High
$24.90
$13.50

Technical Indicators

Market Signals
Indicator
INBS
BIAF
Relative Strength Index (RSI) 53.77 40.77
Support Level $2.26 $0.33
Resistance Level $3.16 $1.45
Average True Range (ATR) 0.32 0.07
MACD 0.07 0.02
Stochastic Oscillator 45.54 10.24

Price Performance

Historical Comparison
INBS
BIAF

About INBS Intelligent Bio Solutions Inc.

Intelligent Bio Solutions Inc is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. Its Biosensor Platform is developing and launching diagnostic tests urgently needed to help people living with chronic diseases. It also engages in the advancement of portable drug abuse testing through the analysis of fingerprint sweat. The test is non-invasive, hygienic, and fast, and screens for recent use of opioids, cocaine, methamphetamines, benzodiazepines, and marijuana. The company operates through new reportable segments: United Kingdom; Asia Pacific (APAC); Americas; and Rest of World, of which United Kingdom derives maximum revenue.

About BIAF bioAffinity Technologies Inc.

bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.

Share on Social Networks: